Publications

Genoskin newly developed InflammaSkin®, a T cell-driven skin inflammation model for psoriasis. With adipose, this cutting-edge assay is designed to assess the efficacy of subcutaneously-delivered anti-inflammatory treatments.

For the first time, we demonstrated that NativeSkin® can be cultured for up to 10 days while preserving normal skin integrity, significant cell viability,  proliferative cells and low levels of apoptosis. Our next step will be to evaluate the activity of specific human skin cytochromes involved in the metabolization of drugs topically applied on NativeSkin®.

Wounded HypoSkin® model is suitable to study wound infection. This model presents the ability to evaluate topical therapies and dressings in prophylactic administration, to prevent wound infection, or in therapeutic treatment, for infected wounds.

HypoSkin® is a fully functional ex vivo human skin model that is relevant to study human skin microbiome and to assess changes in skin microbiota following treatment with dermo-cosmetic products.

InflammaSkin® is a T-cell driven ex vivo human psoriasis skin model to test anti-inflammatory drugs. This skin model can be used to assess pharmacological responses following topical prophylactic and therapeutic treatments.

NativeSkin® is a patented human skin model reproducing the complexity of real live human skin. It allows culture, treatment, and manipulation of human skin for research and analysis. This model can be used to predict human skin response to treatments. In particular, the presence of immune cells enables the study of allergen uptake during epicutaneous immunotherapy.

Light-sheet fluorescence microscopy (LSFM) is an attractive approach that has shown promise for acquisition of volumetric data of thick tissues. When combined with optical clearing methods, LSFM allows in-depth optical sectioning and generation of 3D images of entire human skin biopsies.

HypoSkin® is the only human skin model to study subcutaneous injections. It contains all three layers of human skin, i.e. epidermis, dermis and hypodermis with normal fat tissue architecture.  This model enables the evaluation of local inflammatory reactions following subcutaneous injection of formulations.